Thursday, November 19, 2026Thu, Nov 19

Moon: waxing gibbous, 72% litAurora: quiet

Español

Space, Earth and the natural world, explained.

Rare Fever Disease Traced to Faulty NK Cells, Not Macrophages

Garvan researchers found that misfiring natural killer cells drive mevalonate kinase deficiency, a rare inflammatory disorder, in a study in Immunity.

Microscopic image showcasing the intricate structure and texture of plant cells.
Photo: turek / Pexels

Natural killer cells, a type of immune cell that normally destroys infected cells, malfunction in people with a rare genetic disorder called mevalonate kinase deficiency (MKD) and set off its dangerous inflammation, researchers at the Garvan Institute of Medical Research in Australia report. The finding challenges about 30 years of thinking, which put the blame on a different cell type, the macrophage.

MKD causes recurring attacks of high fever, skin rashes, joint pain and inflammation in the abdomen. The worst episodes can be life-threatening. It is known to affect hundreds of children and adults worldwide, and the researchers suspect many more people have it without a diagnosis.

What the Garvan team measured

For roughly three decades, MKD research centered on macrophages, which help coordinate the body’s inflammatory defenses. Current treatments block an inflammatory signal that these cells release. About half of patients do not respond well enough to them, according to the institute.

The Garvan team looked elsewhere. They examined blood samples from people with MKD and ran experiments in preclinical models of the disorder. In both, natural killer (NK) cells showed a clear defect. The cells did not mature properly and were poor at their main job of killing infected cells before an infection spreads.

NK cells kill with toxic granules, small packets of destructive molecules. Professor Mike Rogers, the senior author, said that in MKD these granules cannot be released and stay trapped inside the cell. A cell that fails to kill its target then pumps out large amounts of interferon gamma, a strong inflammatory signal. That signal activates other immune cells and produces the fever and widespread inflammation seen in patients.

Working with scientists at Monash University, the team used preclinical models to connect the faulty NK cells to the severe symptoms. When the immune system could not clear a viral infection, the resulting inflammation damaged organs extensively.

Dr. Marcia Munoz, the study’s lead researcher, said: “This really turns on its head 30 years of dogma about what was thought to be the underlying mechanism of disease.”

An existing drug in one infant

The result has already shaped an experimental treatment. With doctors at the Royal Children’s Hospital in Melbourne, the researchers tried baricitinib in a severely affected infant. Baricitinib belongs to a group of drugs called JAK inhibitors, which interfere with immune signaling pathways, including those that respond to interferon gamma. It is already used for other immune-related conditions, including rheumatoid arthritis and eczema.

Doctors added the drug to the child’s existing treatment. Inflammatory flare-ups became less frequent, and severe inflammation in the gastrointestinal tract began to heal.

How sure is this?

The work was published in the journal Immunity (DOI 10.1016/j.immuni.2026.03.027), a peer-reviewed venue, with Munoz and Rogers among a long list of authors. The mechanism rests on patient blood samples and preclinical models, and the researchers describe the NK cell defect as a new target rather than a proven cure.

The drug result comes from one patient. The institute’s own account says a single case cannot show whether the treatment will work more broadly, and calls the improvement encouraging early evidence. No clinical trial of JAK inhibitors in MKD has been reported yet. Patients should not read this as a reason to change any treatment, and decisions about therapy belong with their doctors.

What comes next

Rogers said the study “sets the scene for future clinical studies” of JAK inhibitors or other drugs that neutralize interferon gamma in people with MKD, particularly those who have not benefited from standard treatments.

The researchers also propose the term “prenylopathies” for a family of genetic disorders that involve the same metabolic pathway as MKD. Early findings suggest these diseases may share the same problem, with NK cells that fail to work properly and release excessive inflammatory signals. If further studies confirm it, scientists could find common mechanisms and develop more targeted diagnosis and treatment across several disorders. Rogers said that confirmation could help end the years or even decades many patients spend searching for a diagnosis.

For background on how these cells fit into the body’s defenses, see our explainer on how the immune system works.

Source: ScienceDaily

Site editor: Nikita Sheikin